ABSTRACT BACKGROUND: To examine the effects of adropin on glucose and lipid metabolism in a rat model of Type 2 diabetes mellitus (T2DM). METHODS: T2DM were established using high-fat diet and streptozocin (STZ; 35 mg/kg/b.w.). Seven days after STZ induction, diabetic rats were randomly treated with adropin (2.1 μg/kg/day intraperitonealy) for 10 days. The study involved the evaluation of biochemical parameters, including blood glucose, total cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma glutamyl transferase (GGT) activities. Additionally, Tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) and inducible nitric oxide synthase (iNOS) mRNA gene expressions in pancreas tissue were determined by reverse transcription-polymerase chain reaction. RESULTS: The serum levels of insulin and adropin were determined by ELISA. Treatment with adropin showed a signifi cant reduction in blood glucose levels, HbA1c (%), HOMA-IR and increase in HOMA-β, serum insulin levels. In addition, intraperitoneal adropin application can reduce serum levels of TC, TG, LDL-C, and increase level of HDL-C. Adropin also effectively ameliorated the alterations in TNF-α, IL-6 and iNOS mRNA expression. CONCLUSION: The present study indicates that the adropin possesses antidiabetic and antidyslipidemic effects in T2DM (Tab. 2, Fig. 3, Ref. 32). Text in PDF www.elis.sk. KEY WORDS: adropin, type 2 diabetic rat, blood glucose, insulin, high fat diet.
Introduction
Diabetes mellitus is a common metabolic syndrome affecting more than 170 million individuals worldwide (1), among which ~90 % are classifi ed as type 2 diabetes (2). Insulin resistance, arising primarily in peripheral tissue and liver, is the main reason accounting for hyperglycemia in obesity and type 2 diabetes (2). Thus, understanding the regulation of the insulin response and identifying the related mechanisms are important to early treatment and prevention of type 2 diabetes mellitus.
A new metabolic hormone, adropin, was isolated in 2008 by Kumar et al where the coding Enho gene (energy homeostasis associated) was found to be expressed in the liver and the brain of mice (3). Celik et al (4) showed that the mean maternal and cord serum adropin concentration is lower in women with gestational diabetes mellitus than controls. Kumar et al have also indicated an association between adropin defi ciency, increased adiposity, and insulin resistance (3) . Adropin could therefore be a factor regulating glucose and lipid homeostasis, which protects against the hepatosteatosis and hyperinsulinemia associated with obesity. This peptide is expressed in rat brain, cerebellum, kidneys, heart, liver, and pancreas and its levels are increased in streptozotocininduced diabetes (5) .
Adropin is a highly conserved polypeptide that has been suggested to act as an endocrine factor that plays important roles in metabolic regulation, insulin sensitivity, and endothelial functions. Adropin is an established modality in the treatment of T2DM although their effects and functions are still unclear. Literature information showing the relationship between adropin and T2DM is very limited. Therefore, we hypothesized a possible curative effect of adropin, which we examined on rats with type 2 diabetes induced by high fat-diet and streptozotocin.
Materials and methods

Animals
Twenty four adult female Wistar albino rats (Dumlupinar University Experimental Animal Laboratory, Kütahya, Turkey) weighing 250-300 g were used. All rats were kept under envi-ronmentally controlled conditions in an air-conditioned room at 21 °C, with appropriate humidity and a 12 h:12 h light: dark cycle and were fed standard rat chow and water ad libitum. This project was approved by the Dumlupinar University Ethics Committee of Animal Care and Usage, Kütahya, Turkey.
Induction of experimental diabetes
Diabetes was induced in rats by orally feeding them with high fat emulsion (10 mL/kg) (6) for 2 weeks. After 2 weeks, the animals were kept in an overnight fast and injected with single dose STZ (35 mg/kg body weight in 0.1 M citrate buffer pH 4.5, intraperitonealy) (7) . One week after the STZ injection, the nonfasting blood glucose levels of all animals were measured in the blood collected from the tail vein by using a portable glucometer (eBsensor, Turkey). The animals with blood glucose levels higher than 300 mg/dL were accepted for inclusion as diabetic.
Experimental design
The female animals were selected randomly and divided into three experimental groups of eight animals each: Group I served as the control (C) receiving saline as vehicle. Group II diabetic rats (D) served as the diabetic control rats. Group III (DA); diabetic rats were treated with adropin at a dosage of 2.1 μg/kg/day intraperitonealy for 10 days.
Tissue preparation and blood sampling
At the end of the experimental period, all animals were anesthetized with Ketamin/Xylazine HCl (75 mg/kg/10 mg/kg intraperitoneally). Blood sample was collected from the aorta in a glass tube to clot for 2 h at room temperature and centrifuged for 20 min to obtain serum for insulin and adropin analysis. Serum was stored at −80 °C. Pancreas tissue samples were then collected in liquid nitrogen for analysis of molecular biologic studies, and stored at -80 °C until analysis.
Biochemical analyses
Serum concentrations of insulin and adropin were analyzed with rat ELISA assay kit using the chemiluminescence method (Cusabio, China) according to the instruction of manufacturer by the ELISA microplate reader (Spectrostar Nano, BMG, Labtech, Germany). The serum concentrations of TC, TG, HDL-C, LDL-C, AST, ALT, ALP and GGT activities were measured by using the Beckman Coulter AU680 analyzer (Beckman Coulter, Miami, FL, USA).
For glycosylated hemoglobin A1c (HbA1c,%) measurements, blood samples were collected into 2.0 mL dipotassium (K2) ethylene diamine tetraacetic acid (EDTA) vacuum tubes (BD Vacuteiner® BD-Plymouth, UK). After blood samples were collected, HbA1C measurement was immediately performed without a delay. Measurement of HbA1C was performed on Tosoh G8 HPLC Analyzer (Tosoh Bioscience, Inc., San Francisco, CA).
Homeostatic model assessment (HOMA-IR) score was calculated using fasting serum insulin and fasting blood glucose concentrations measured at the end of the experimental period according to the following formula: HOMA-IR [(Fasting serum insulin in U/L X fasting blood glucose in mmol/L)/22.5]. β-cell function was quantifi ed with the HOMA-β, with the formula [serum insulin (U/L)×20/glucose (mmol/L) − 3.5] (8).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA isolation was extracted from pancreas tissue samples by the GeneJET RNA Purifi cation Kit (Thermo, Cat No: # K0732) according to the manufacturer's protocol. Total mRNA concentrations were measured at 260 nm using a Maestro Nano Micro-Volume spectrophotometer (Maestrogen Inc., Las Vegas, NV). Samples were stored at -80 °C until further analysis. Complementary DNAs (cDNA) were synthesized by EasyScript™ cDNA Synthesis Kit (abm). cDNAs were stored at -20 °C until used in the RT-PCR PCR was carried out in a total volume of 25 μl containing DNA template, 10XPCR-buffer, PCR grade H 2 O, 25 mmol/L MgCl 2 and 10 mmol/L concentration of primers. RT-PCR was performed according to the manufacturer's instructions. The forward and reverse primers for TNF-α were 5′-CCA CCA CGC TCT TCT GTC TAC-3′ and 5′-GCT ACG GGC TTG TCA CTC G-3′, 148 bp, for IL-6 were 5′-CTT CCA GCC AGT TGC CTT CTT G-3′ and 5′-TGG TCT GTT GTG GGT GGT ATC C-3′, 109 bp, for iNOS were 5′-TTG GAG CGA GTT GTG GAT TGT TGT TC-3′ and 5′-GGT GAG GGC TTG CCT GAG TG AGC-3′, 126 bp. As a control for the presence of amplifi able RNA, β-actin primers were designed. The forward and reverse primers for β-actin were 5'-CTA TCG GCA ATG AGC GGT TCC -3' and 5'-TGT GTT GGC ATA GAG GTC TTT ACG -3', 147 bp. The PCR products were electrophoresed in 2 % agarose gel and stained with ethidium bromide, making sure to include DNA markers of appropriate size. The densitometry of each PCR band was measured and analyzed by the image J program. Optical density was calculated for gene products and results were expressed as the ratio of the density of TNF-α, IL-6, iNOS mRNA to β-actin mRNA.
Statistical analysis
Statistical analysis was done with the SPSS (Statistical Package for Social Sciences, Chicago, IL, USA) 16.0 pocket program. All results were given as the mean ± standard error (SE). Comparisons among multiple groups were done with the Kruskal-Wallis test, and between the two groups with the Mann-Whitney U test. Values lower than p≤0.05 were accepted as statistically signifi cant. Table 1 depicts the levels of blood glucose, HbA1c (%), HOMA-IR, HOMA-β, serum insulin and adropin of C, D and DA groups of rats. There were statistically signifi cant differences in blood glucose, HbA1c (%), HOMA-IR, HOMA-β and adropin levels among the groups C, D and DA (p < 0.05). The diabetic rats showed a signifi cant (p < 0.05) increase in the levels of glucose, HbA1c (%), HOMA-IR, while a reduction in HOMA-β and adropin levels was comparable with C and DA groups. Signifi cant differ-ences were not observed in the levels of serum insulin among the groups C, D and DA (p = 0.183). In addition, low levels of serum insulin were not signifi cant in the D group compared to C group, but were signifi cant compared to DA group.
Results
Effect of adropin on blood glucose, HbA1c (%), HOMA-IR, HOMA-β, serum insulin and adropin levels
Adropin treatment resulted in a decrease in the blood glucose level when compared to diabetic rats. The serum insulin level was statistically signifi cant higher in the DA group than in the D group (p = 0.05). And, also adropin treatment resulted in the improvement in the aberrations in HbA1c (%), HOMA-IR and HOMA-β. In addition, it was observed that serum adropin was signifi cantly higher in the DA group compared to the D group. Table 2 depicts the levels of serum TC, TG, HDL-C, LDL-C, AST, ALT, ALP, GGT activities of C, D and DA groups of rats.
Effect of adropin on lipids and liver enzyme markers
There were statistically signifi cant differences in serum TC, TG, HDL-C and LDL-C levels among the groups of C, D and DA (p = 0.030, p = 0.038, p = 0.008 and p = 0.046). The low level of HDL-C was found in the D and DA groups compared to the C group (p ≤ 0.05). However, the levels of serum TC, TG in the D group were signifi cantly higher than in the C and DA groups (p ≤ 0.05). A signifi cant decrease in serum TC, TG, LDL-C levels (p = 0.021, p = 0.002 and p = 0.021) and a signifi cant increase in the HDL-C levels (p = 0.038) were observed in the DA group when compared to D group (Tab. 2).
There were statistically signifi cant differences in serum AST and ALT levels among the groups of C, D and DA (p = 0.000 and p = 0.000). The level of serum AST and ALT was increased signifi cantly (p ≤ 0.05) in the D group. Treatment with the adropin resulted in a signifi cant decrease in serum AST and ALT levels (Tab. 2).
The differences in the serum ALP among the C, D and DA groups were not signifi cant (p = 0.063). However, the level of serum ALP in the D group was signifi cantly higher than in the C group (p = 0.015). There were statistically signifi cant differences in serum GGT levels among the groups of C, D and DA (p = 0.001). In addition, the level of serum GGT was increased signifi cantly (p ≤ 0.05) in the D group. Treatment with the adropin resulted in a signifi cant decrease in serum GGT levels (Tab. 2). Figure 1 shows the mRNA expression of TNF-α in the pancreas of C, D and DA groups. The differences in the TNF-α gene mRNA expression levels in the pancreas tissue among C (0.91 ± 0.09), D (2.24 ± 0.74) and DA (0.87 ± 0.09) groups were significant (p = 0.014). The expression of TNF-α was increased in the AST -aspartate transaminase, ALT -alanine transaminase, ALP -alkaline phosphatase, GGT -gama glutamyl transferase, p -shows the differences between all groups (Kruskal-Wallis test), a,b,c -in each line, the differences between the mean with the same letters are signifi cant, p ≤ 0.05 (Mann-Whitney U test). The iNOS gene mRNA expression levels in the DA group were signifi cantly lower than in the C and D groups, which were p = 0.05 and p = 0.007, respectively.
Levels of TNF-α, IL-6 and iNOS gene mRNA expression in the pancreas tissue
Tab. 2. Effect of adropin on lipids and liver enzyme markers of Control (C), Diabetes (D) and
Discussion
Type 2 diabetes mellitus is the most common form of the metabolic disorder, which is caused by an impaired insulin secretion paralleled by a progressive decline in β cell function and chronic insulin resistance (9) . Insulin resistance and β cell dysfunction are the important characteristics of T2DM. In addition, the pathogenesis of T2DM was very complicated and associated with insulin resistance and secretion defi ciency (10), infl ammatory reaction (11) , and oxidative stress (12) . Therefore, we studied the effect of adropin on blood glucose and insulin levels and also performed HOMA-IR and HOMA-β to check the degree of insulin resistance and beta cell function.
In this study, a signifi cant increase was observed in the proportion of blood glucose HbA1c (%) and HOMA-IR scores, while HOMA-β was decreased in STZ-treated type 2 diabetic rats. In addition, there were no signifi cant decreases in the serum level of insulin in the D group compared to the C and DA groups. In the study by Mahmoud et al (13) , it was observed that type 2 diabetic rats exhibited a signifi cantly elevated fasting blood glucose and HOMA-IR, accompanied with diminished serum insulin levels, and insulin resistance has developed in these animals (13). Huang et al (14) reported that HbA1c (%) levels, the indicator of diabetes, were signifi cantly increased in type 2 diabetes mellitus rats (14) . Estimation of HbA1c% has been found to be particularly useful in monitoring the effectiveness of therapy in diabetes (15) . These results seem to be compatible with our study results and can be considered as the indicator of forming type 2 diabetes in rats.
In this study, serum adropin levels were signifi cantly reduced in the D group compared to the C and DA groups. Wu et al (16) have demonstrated that serum adropin level was signifi cantly lower in type 2 diabetic patients compared to non-diabetic patients. Celik et al (4) showed that mothers with gestational diabetes had lower adropin concentrations in their blood (4) . Previous study has shown that (5) adropin is expressed in various tissues as pancreas, liver, kidney, heart in the rats and its levels increased in STZ-induced diabetes. In this study, the expression of adropin in rat pancreas tissues was not considered.
In our study, intraperitonel administration of adropin significantly decreased the levels of fasting blood glucose, HOMA-IR and HbA1c (%) and increased the levels of HOMA-β, serum insulin and adropin in the DA group. Yildirim et al (17) recently showed that serum adropin level was negatively correlated with fasting serum insulin levels, HOMA-IR in polycystic ovarian syndrome patients (p < 0.05). Aydin et al (18) reported that there was a negative correlation between HbA1c (%) and adropin concentrations. The study demonstrated that lower adropin levels were associated with insulin resistance in humans, as was the case in mice (19) . In the study performed by Kumar (3) , it was shown that elevated amounts of adropin in circulation reduced insulin resistance and glucose intolerance that occured in response to metabolic stress (3). These results indicated the benefi cial effects of adropin in preventing the diabetic complications caused by an impaired glucose metabolism.
In our study, signifi cant decrease in HDL-C levels and a signifi cant increase in the serum TC, TG, LDL-C levels were ob- served in the D group when compared to the DA group. In the studies performed on type 2 diabetic rats, upregulation of TC, TG, LDL-C levels and downregulation of HDL-C levels were reported when compared to the control group (20, 21) . After the treatment of adropin, it was found that adropin could remarkably lower the levels of fasting blood glucose, TC, TG and LDL-C, while could also increase the level of HDL-C in the DA group. The previous study by Bulter et al (22) demonstrated that adropin levels correlated negatively with TG in metabolic syndrome patients after a gastric bypass surgery (22) . Yildirim et al (17) recently showed that serum adropin level was correlated negatively with serum lipid markers including cholesterol, very low-density lipoprotein, and triglycerides in PCOS patients (p < 0.05). Our present results demonstrated that adropin could decrease the elevated activity of lipids in type 2 diabetic rats. This may be benefi cial in the amelioration of the type 2 diabetic state.
In our study, the elevated activities of AST, ALT, ALP and GGT shown in diabetic rats signifi cantly decreased in diabetic rats upon intraperitoneal treatment with adropin. Several researchers reported that the elevated activities of AST, ALT and ALP enzymes were indicative of cellular damage and loss of the functional integrity of the cell membranes (23, 24) . Soufi et al (25) depicted that levels of hepatic marker enzymes as AST, ALT and ALP in diabetic rats were increased. After the treatment of adropin, it was found that adropin could decrease the level of AST, ALT, ALP and GGT in the DA group. There has not been any study in literature between adropin and hepatic marker enzymes that can be compared with the results of this study. Our present results demonstrated that adropin could decrease the elevated AST, ALT, ALP and GGT activities and had potential hepatoprotective effects in type 2 diabetic rats.
In this study, TNF-α and IL-6 mRNA expression in the pancreas tissue was signifi cantly increased in the D group compared to the C group. Liu et al (26) demonstrated that serum TNF-α and IL-6 levels also showed a signifi cant increase in T2DM rats. Earlier workers reported that elevated levels of TNF-α and IL-6 caused insulin resistance and had a direct cytotoxic effect on pancreatic β-cells in T2DM (27, 28) . This study's results are compatible with the aforementioned study. Adropin appeared to inhibit expression of infl ammatory cytokines in pancreas, such as TNF-α and IL-6 in the DA group. There was no study in literature between adropin, TNF-α and IL-6 that could be compared with the results of this study. In the animal study conducted in 2010, Lovren et al (29) reported that adropin-treated endothelial cells demonstrated a higher proliferation, migration, and capillary-like tube formation as well as lower permeability and tumour necrosis factor-alpha-induced apoptosis (29) .
In this study, iNOS mRNA expression in the pancreas tissue was signifi cantly increased in the D group compared to the C group. The study by Kataoka et al (30) showed that the expression of both iNOS and the TNF-α, IL-6 mRNA levels increased in rats with type 2 diabetes mellitus. He et al (31) indicated that the expression of iNOS was increased in the pancreas in STZ-induced diabetic rats. A signifi cant decrease in the iNOS mRNA expression in the DA group was seen when compared to the C and D groups. Kuloglu et al (32) showed that the intensities of adropin and iNOS immunoreactivity increased with the severity of the diabetes. In addition, the elevated levels of adropin and iNOS in the kidney indicated that these substances were involved in the pathophysiology of diabetes; this constitutes a compensatory mechanism against the damage infl icted by the disease (32). An increased expression of TNF-α, IL-6 and iNOS mRNA seen in diabetic rats was decreased in adropin treated rats. This showed the activity of the adropin in improving the insulin sensitivity. Our present results demonstrated that adropin suppressed infl ammation effects in type 2 diabetic rats.
In conclusion, adropin exhibited a signifi cant antidiabetic activity, presumably by inhibiting infl ammatory cytokines, improving glucose metabolism, insulin sensitivity and serum lipid and liver enzyme markers in high fat diet + streptozotocin induced type 2 diabetic model and might be a potential target for diabetes treatment.
